Osteoinduction via growth factor release

Osteoinduction via growth factor release refers to the biological process by which growth factors, when released in the microenvironment (often from a scaffold or graft), induce the differentiation of mesenchymal stem or progenitor cells into bone-forming osteoblasts[8][1][3][6]. Key growth factors that mediate this process include bone morphogenetic proteins (BMPs), transforming growth factor-beta (TGF-β), fibroblast growth factors (FGFs), and platelet-derived growth factor (PDGF). These factors bind to their respective cell-surface receptors, activating intracellular signaling cascades that culminate in upregulation of osteogenic gene expression—most notably via the RUNX2 pathway and SMAD-dependent signaling in the case of BMPs and TGF-β[6][2][3]. Osteoinduction is essential for bone grafting, dental implant integration, and general bone tissue regeneration therapies[8]. Clinical applications most often utilize recombinant growth factors such as rhBMP-2 or BMP-7, delivered locally via biomaterial scaffolds that control temporal and spatial release to optimize regeneration and minimize adverse effects[1][5][7]. The concept itself is a biological function, not a discrete molecular target, so it should not be curated as a canonical druggable target.

Other names

Osteoinductive growth factor-mediated bone formationOsteoinduction by growth factor deliveryGrowth factor-mediated osteoinduction

Induction of mesenchymal stem cell differentiation into osteoblasts via activation of signaling pathways downstream of growth factor receptors[8][2][3][6].